11 Einträge gefunden

1. Medication Adherence in a Cross-Diagnostic Sample of Patients From the Affective-to-Psychotic Spectrum: Results From the PsyCourse Study

   1. Kirchner, Sophie-Kathrin
   2. Lauseker, Michael
   3. Adorjan, Kristina
   4. Anderson-Schmidt, Heike
   5. Anghelescu, Ion-George
   6. Baune, Bernhardt T
   7. Budde, Monika

   2022 - Forschungsinformationssystem des UKE - frei zugänglich
2. High-risk additional chromosomal abnormalities at low blast counts herald death by CML

   1. Hehlmann, Rüdiger
   2. Voskanyan, Astghik
   3. Lauseker, Michael
   4. Pfirrmann, Markus
   5. Kalmanti, Lida
   6. Rinaldetti, Sebastien
   7. Kohlbrenner, Katharina

   2020 - Forschungsinformationssystem des UKE
3. Correction: High-risk additional chromosomal abnormalities at low blast counts herald death by CML

   1. Hehlmann, Rüdiger
   2. Voskanyan, Astghik
   3. Lauseker, Michael
   4. Pfirrmann, Markus
   5. Kalmanti, Lida
   6. Rinaldetti, Sebastien
   7. Kohlbrenner, Katharina

   2020 - Forschungsinformationssystem des UKE
4. Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV

   1. Michel, Christian
   2. Burchert, Andreas
   3. Hochhaus, Andreas
   4. Saussele, Susanne
   5. Neubauer, Andreas
   6. Lauseker, Michael
   7. Krause, Stefan W

   2019 - Forschungsinformationssystem des UKE - frei zugänglich
5. The role of GSK3 and its reversal with GSK3 antagonism in everolimus resistance

   1. Aristizabal Prada, Elke Tatjana
   2. Spöttl, Gerald
   3. Maurer, Julian
   4. Lauseker, Michael
   5. Koziolek, Eva Jolanthe
   6. Schrader, Jörg
   7. Grossman, Ashley

   2018 - Forschungsinformationssystem des UKE
6. The selective PI3Kα inhibitor BYL719 as a novel therapeutic option for neuroendocrine tumors: Results from multiple cell line models

   1. Nölting, Svenja
   2. Rentsch, Jakob
   3. Freitag, Helma
   4. Detjen, Katharina
   5. Briest, Franziska
   6. Möbs, Markus
   7. Weissmann, Victoria

   2017 - Forschungsinformationssystem des UKE - frei zugänglich
7. Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV

   1. Hehlmann, Rüdiger
   2. Müller, Martin C
   3. Lauseker, Michael
   4. Hanfstein, Benjamin
   5. Fabarius, Alice
   6. Schreiber, Annette
   7. Proetel, Ulrike

   2014 - Forschungsinformationssystem des UKE
8. Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators: results from the randomized CML study IV

   1. Kalmanti, Lida
   2. Saussele, Susanne
   3. Lauseker, Michael
   4. Proetel, Ulrike
   5. Müller, Martin C
   6. Hanfstein, Benjamin
   7. Schreiber, Annette

   2014 - Forschungsinformationssystem des UKE
9. Older patients with chronic myeloid leukemia (≥65 years) profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IV

   1. Proetel, Ulrike
   2. Pletsch, Nadine
   3. Lauseker, Michael
   4. Müller, Martin C
   5. Hanfstein, Benjamin
   6. Krause, Stefan W
   7. Kalmanti, Lida

   2014 - Forschungsinformationssystem des UKE
10. Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-α in newly diagnosed chronic myeloid leukemia.

    1. Hehlmann, Rüdiger
    2. Lauseker, Michael
    3. Jung-Munkwitz, Susanne
    4. Leitner, Armin
    5. Müller, Martin C
    6. Pletsch, Nadine
    7. Proetel, Ulrike

    2011 - Forschungsinformationssystem des UKE
11. Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV.

    1. Saussele, Susanne
    2. Lauseker, Michael
    3. Gratwohl, Alois
    4. Beelen, Dietrich W
    5. Bunjes, Donald
    6. Schwerdtfeger, Rainer
    7. Kolb, Hans-Jochem

    2009 - Forschungsinformationssystem des UKE